Objective: To investigate the use of antiasthmatic drugs in hospitalized children with asthmatic bronchopneumonia in a primary hospital. Methods: Retrospectively analysis was performed on clinical data of use of antiasthmatic drugs in 192 children with asthmatic bronchopneumonia admitted into a primary hospital from Aug. to Dec. of 2017. Results: Infants and young children were the main group of patients with asthmatic bronchopneumonia

among which males account for 70.83%. Antiasthmatic treatment was mainly given by aerosol inhalation alone

followed by aerosol inhalation combined with oral administration

aerosol inhalation combined with intravenous administration

aerosol inhalation combined oral administration and intravenous administration. Aerosol inhalation mainly consisted of budesonide suspension for inhalation + salbutamol solution for inhalation + ipratropium bromide for inhalation

accounting for 81.25%. The consumption sum of budesonide suspension for inhalation was higher

accounting for 73.9% of the total cost of nebulized inhalation drugs. Conclusion: The asthmatic bronchopneumonia treatment is based on nebulized inhalation therapy

antiasthmatic regimens should be individualized to ensure the safety of antiasthmatic treatment for children.